tetano
Editor, Senior Moderator
J Int Med Res
. 2023 Sep;51(9):3000605231198413.
doi: 10.1177/03000605231198413. Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study
Randa Farah[SUP] 1 [/SUP], Hussam Al-Hawari[SUP] 2 [/SUP], Asma Albtoush[SUP] 3 [/SUP], Amani Nofal[SUP] 4 [/SUP], Tala Basheer Hyasat[SUP] 4 [/SUP], Raghed Abdel Hay Abu Jabeh[SUP] 4 [/SUP], Lojayn Tareq Suboh[SUP] 4 [/SUP], Ahmad A Toubasi[SUP] 3 [/SUP], Tareq Fatah Eqrai[SUP] 5 [/SUP], Mohammad Abufaraj[SUP] 6 [/SUP]
Affiliations
Objectives: The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM.
Methods: In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection.
Results: Among 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0-0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1-0.9).
Conclusion: Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.
Keywords: COVID-19; COVID-19 vaccine; Type 2 diabetes mellitus; infection control; lung fibrosis; mortality; risk assessment.
. 2023 Sep;51(9):3000605231198413.
doi: 10.1177/03000605231198413. Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study
Randa Farah[SUP] 1 [/SUP], Hussam Al-Hawari[SUP] 2 [/SUP], Asma Albtoush[SUP] 3 [/SUP], Amani Nofal[SUP] 4 [/SUP], Tala Basheer Hyasat[SUP] 4 [/SUP], Raghed Abdel Hay Abu Jabeh[SUP] 4 [/SUP], Lojayn Tareq Suboh[SUP] 4 [/SUP], Ahmad A Toubasi[SUP] 3 [/SUP], Tareq Fatah Eqrai[SUP] 5 [/SUP], Mohammad Abufaraj[SUP] 6 [/SUP]
Affiliations
- PMID: 37728611
- DOI: 10.1177/03000605231198413
Objectives: The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM.
Methods: In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection.
Results: Among 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0-0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1-0.9).
Conclusion: Patients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.
Keywords: COVID-19; COVID-19 vaccine; Type 2 diabetes mellitus; infection control; lung fibrosis; mortality; risk assessment.